Trial | NCT02796105  Report issue

Title

Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors
Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    232
Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors
Study Started
Jun 30
2016
Primary Completion
Jul 31
2017
Study Completion
Jul 10
2017
Last Update
Sep 13
2017

Drug Progevera

Drug Orgalutran

Progevera Experimental

Progevera 10 mg

Orgalutran Active Comparator

Orgalutran 0.25 mg

Criteria 

Inclusion Criteria:

Oocyte donors included in the oocyte donation program of Clinica EUGIN.
1st oocyte donation cycle at Clínica EUGIN.

Exclusion Criteria:

Polycistic Ovarian syndrome (PCOs).
Estradiol levels on day 2 of menstrual cycle >70 pg/ml.
Hormone treatments up to 3 months before the oocyte donation cycle.
Medical contraindication to the treatments used in the study
No Results Posted